Short Interest in Swedish Orphan Biovitrum (OTCMKTS:BIOVF) Rises By 139.7%

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) saw a large growth in short interest in July. As of July 31st, there was short interest totaling 649,723 shares, a growth of 139.7% from the July 15th total of 271,067 shares. Based on an average daily trading volume, of 252 shares, the short-interest ratio is presently 2,578.3 days. Currently, 0.2% of the company’s stock are sold short.

Analysts Set New Price Targets

A number of research firms have commented on BIOVF. Zacks Research upgraded Swedish Orphan Biovitrum to a “hold” rating in a research note on Thursday, May 7th. HC Wainwright started coverage on shares of Swedish Orphan Biovitrum in a report on Wednesday, May 6th. They set a “buy” rating on the stock. Barclays reaffirmed an “overweight” rating on shares of Swedish Orphan Biovitrum in a research report on Friday, July 3rd. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of Swedish Orphan Biovitrum in a research note on Tuesday, July 21st. Finally, Pareto Securities downgraded shares of Swedish Orphan Biovitrum to a “hold” rating in a research report on Monday, June 29th. Four analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy”.

Swedish Orphan Biovitrum Price Performance

Swedish Orphan Biovitrum stock opened at $48.20 on Friday. The company has a debt-to-equity ratio of 0.20, a quick ratio of 0.55 and a current ratio of 0.88. The business’s 50-day simple moving average is $48.32 and its two-hundred day simple moving average is $43.82. The company has a market cap of $17.16 billion, a PE ratio of 107.12 and a beta of 0.35. Swedish Orphan Biovitrum has a fifty-two week low of $28.93 and a fifty-two week high of $49.03.

About Swedish Orphan Biovitrum

Swedish Orphan Biovitrum AB (publ), commonly known as Sobi, is a Stockholm‐based biopharmaceutical company specializing in the development, manufacturing and commercialization of treatments for rare diseases. Formed in 2010 through the merger of Swedish Orphan International AB (established 1985) and Biovitrum AB, the company focuses on high‐value therapies in hematology, immunology, oncology and genetic/metabolic disorders. Sobi’s strategy centers on building a global specialty care portfolio by in‐licensing, acquiring and internally developing innovative products aimed at small patient populations with significant unmet needs.

The company’s marketed portfolio includes recombinant clotting factor therapies such as Elocta (rFVIIIFc) and Alprolix (rFIXFc) for hemophilia A and B, respectively; Ruconest, a recombinant human C1 esterase inhibitor for hereditary angioedema; and Kineret (anakinra) for certain auto‐inflammatory conditions.